Objective. This study aimed to investigate the correlation of CD4+/PD-1+ or CD4+/PD-1− tumor-infiltrating lymphocytes with pathological characteristics in breast cancer patients. Methods. A cross-sectional study consecutively recruited 133 patients with invasive ductal breast cancer. The expression of CD4, programmed cell death protein 1 (PD-1), CK7, CK20, E-cadherin, or Ki-67 was detected by immunohistochemistry. The associations between CD4+/PD-1+ or CD4+/PD-1− tumor-infiltrating lymphocytes and pathological characteristics were evaluated. Results. Elderly patients intended to have a lower level of CD4+/PD-1− tumor-infiltrating lymphocytes (p<0.05). Patients with positive E-cadherin expression had higher median cell counts of CD4+/PD-1− t...
BACKGROUND: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controve...
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
Objective. This study is aimed at investigating the association of exhausted CD8+ tumor-infiltrating...
To better understand the expression pattern of programmed death-ligand 1 (PD-L1) expression in diffe...
The clinical relevance of tumor-infiltrating lymphocytes (TIL) in breast cancer (BC) has been clearl...
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer case...
Programmed death 1 (PD-1) is a co-inhibitory receptor in the CD28/CTL-4 family, and functions as a n...
Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 e...
Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 e...
BACKGROUND: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predi...
Introduction: Immunotherapy targeting the programmed death-1 (PD-1) checkpoint has resulted in good ...
Feng Shi,1 Hong Chang,1 Quan Zhou,1 Yan-Jie Zhao,2 Guang-Jiang Wu,3 Qing-Kun Song4,5 1Department of...
Introduction. Prognostic and predictive value of PD-L1 as a biomarker in breast cancer remains contr...
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer...
BACKGROUND: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controve...
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
Objective. This study is aimed at investigating the association of exhausted CD8+ tumor-infiltrating...
To better understand the expression pattern of programmed death-ligand 1 (PD-L1) expression in diffe...
The clinical relevance of tumor-infiltrating lymphocytes (TIL) in breast cancer (BC) has been clearl...
Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer case...
Programmed death 1 (PD-1) is a co-inhibitory receptor in the CD28/CTL-4 family, and functions as a n...
Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 e...
Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 e...
BACKGROUND: Expression of programmed death ligand 1 (PD-L1) in solid tumours has been shown to predi...
Introduction: Immunotherapy targeting the programmed death-1 (PD-1) checkpoint has resulted in good ...
Feng Shi,1 Hong Chang,1 Quan Zhou,1 Yan-Jie Zhao,2 Guang-Jiang Wu,3 Qing-Kun Song4,5 1Department of...
Introduction. Prognostic and predictive value of PD-L1 as a biomarker in breast cancer remains contr...
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer...
BACKGROUND: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controve...
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...